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Abstract
Introduction: Glial fibrillary acidic protein (GFAP) may serve as a serum marker of traumatic brain injury (TBI) that
can be used to monitor biochemical changes in patients and gauge the response to treatment. However, the temporal
profile of serum GFAP in the acute period of brain injury and the associated utility for outcome prediction has not
been elucidated.
Methods: We conducted a prospective longitudinal cohort study of consecutive severe TBI patients in a local tertiary
neurotrauma center in Shanghai, China, between March 2011 and September 2014. All patients were monitored and
managed with a standardized protocol with inclusion of hypothermia and other intensive care treatments. Serum
specimens were collected on admission and then daily for the first 5 days. GFAP levels were measured using enzyme-
linked immunosorbent assay techniques. Patient outcome was assessed at 6 months post injury with the Glasgow
Outcome Scale and further grouped into death versus survival and unfavorable versus favorable.
Results: A total of 67 patients were enrolled in the study. The mean time from injury to admission was 2.6 hours, and
the median admission Glasgow Coma Scale score was 6. Compared with healthy subjects, patients with severe TBI had
increased GFAP levels on admission and over the subsequent 5 days post injury. Serum GFAP levels showed a gradual
reduction from admission to day 3, and then rebounded on day 4 when hypothermia was discontinued with slow
rewarming. GFAP levels were significantly higher in patients who died or had an unfavorable outcome across all time
points than in those who were alive or had a favorable outcome. Results of receiver operating characteristic curve
analysis indicated that serum GFAP at each time point could predict neurological outcome at 6 months. The areas
under the curve for GFAP on admission were 0.761 for death and 0.823 for unfavorable outcome, which were higher
than those for clinical variables such as age, Glasgow Coma Scale score, and pupil reactions.
Conclusions: Serum GFAP levels on admission and during the first 5 days of injury were increased in patients with
severe TBI and were predictive of neurological outcome at 6 months.
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Introduction
The outcomes following severe traumatic brain injury
(TBI) are still poor, despite the great advances achieved in
surgical techniques and intensive care over the past
decades. It is estimated that 39 % of severely brain-injured
patients die from their injury and 60 % are left with poor
outcome [1]. Accurate determination of the extent of pri-
mary brain damage and the ongoing secondary injury after
severe TBI is critical for the establishment of neurological
prognosis and the guidance of appropriate therapeutic
interventions [2]. Clinical characteristics such as the Glas-
gow Coma Scale (GCS) and modern imaging techniques
have markedly improved the early assessment and care of
severe TBI. Nevertheless, there are still concerns regarding
these tools, including inability to manifest the actual
pathophysiological or morphological status in the injured
brain or being prone to influence the use of sedatives,
analgesics, or muscle relaxants in current management
protocols [3–5].
At present, we have no means of successfully monitor-
ing the biochemical responses in the brain following
severe TBI. A set of brain-specific biomarkers, measurable
from accessible biological fluids, were recently reported to
have the ability to reflect the severity and progression of
brain damage, and were used to measure the response to
treatment and offer prognostic information for injured
patients [6–9]. Accurate outcome prediction also allows
the identification of appropriate candidates for risky thera-
peutic strategies, which could limit the unnecessary treat-
ment for patients who would have little possibility of
survival or a favorable outcome [10].
Historically, a wide range of brain damage markers
have been examined in TBI patients. However, owing to
the limited tissue specificity and other concerns, most
markers, including neuro-specific enolase and S100B pro-
tein, were compromised in routine clinical use [11]. Glial
fibrillary acidic protein (GFAP) was recently reported to
have greater prognostic value than other biomarkers in
TBI patients [12]. As a monomeric intermediate filament
protein concentrated in the astroglial cytoskeleton, GFAP
is specific to brain tissue and is not routinely found in
peripheral blood circulation. However, GFAP is released
after astrocyte death, making it an ideal candidate marker
for brain injury patients [13]. Several studies have found
that the serum levels of GFAP on admission were sig-
nificantly increased in TBI patients, while a correlation
between serum concentrations and the pathological
types of brain damage and clinical outcomes were also
reported [14–18]. However, the changes in serum GFAP
over time and the associated predictive utility over the
acute days post injury are largely unknown.
Thus, the aim of this study was to evaluate the time
course of serum GFAP levels in the first several days of
injury, and to determine whether serum GFAP during
this period could predict death and unfavorable outcome
at 6 months for severe TBI patients. Our findings may
be useful for early risk stratification for research and
care of TBI patients.
Methods
Study population
This was a prospective cohort study that examined adult
severe TBI patients admitted to a local neurotrauma
center (Shanghai Institute of Head Trauma) in Shanghai,
China, from March 2011 to September 2014. The insti-
tute, located in the Department of Neurosurgery of a
tertiary teaching hospital (Renji Hospital), admits more
than 400 TBI patients per year and provides 24-hour
neurosurgery facilities and specialized intensive care for
all patients.
The patients were included in the study based on
established criteria, including older than 18 years, an
acute TBI less than 4 hours before admission, a GCS
score of 3–8 after resuscitation, and abnormal head CT
scan on admission. Exclusion criteria were severe com-
bined injury, unstable vital signs after resuscitation such
as systolic blood pressure less than 90 mmHg or oxygen
saturation less than 94 %, and pregnant women. Add-
itionally, a total of 135 healthy blood donors who had
no prior reports of TBI or neurological diseases were
enrolled as the control group, with serum samples
collected and analyzed for comparison.
This study was approved by the ethics committee of
Renji Hospital, Shanghai Jiaotong University School of
Medicine, and written informed consent was obtained
from the control subjects and each severely brain-injured
patient’s legal authorized representative owing to their
comatose state within 24 hours of being deemed eligible.
Treatment protocol
In Renji Hospital, nearly all injured patients were trans-
ported by emergency medical services (EMS) professionals
to the emergency department (ED) shortly after trauma
without intubation or sedation. Thus, we were able to
evaluate the patients without the interference of prehospi-
tal interventions. On their arrival at the ED, patients with
indications of TBI were neurologically assessed, received a
computed tomography (CT) scan of the head, and then
were screened for enrollment in this study. Large intracra-
nial hematomas and hemorrhagic contusions, once con-
firmed by head CT, were evacuated immediately and the
patients then transferred into the neurosurgical intensive
care unit (NICU).
All patients were monitored and managed according to a
standardized institutional protocol including hypothermia
and other intensive care treatments. An intraventricular
catheter or an intraparenchymatous microtransducer was
used for the continuous measurement of intracranial
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pressure (ICP). Mild hypothermia (34–35 °C) was rapidly
induced using cooling blankets (MTRE Advanced Tech-
nologies, Trevose, PA, USA) placed below and above the
patients, which was maintained for as long as 3 days. The
cooled patients were tracheotomized for ventilation, con-
tinuously sedated (chlorpromazine, 5–10 mg/h) and para-
lyzed (atracurium, 10–40 mg/h). During hypothermia, the
systolic blood pressure of the patient was maintained above
90 mmHg, peripheral oxygen saturation greater than 95 %,
ICP less than 25 mmHg, and cerebral perfusion pressure at
a level of 50–70 mmHg. After a 3-day maintenance period,
the patients were passively rewarmed to 36–37 °C at a rate
no greater than 0.5 °C every 4 hours, carefully individual-
ized by the patients’ ICP level. If the rebound of ICP was in-
dicated, then a much slower rewarming rate (<0.5 °C every
8 hours) and the extensive use of other ICP-reducing
measures were employed.
Intracranial hypertension during the whole hospitalization
course was resolved progressively with a set of stepwise
strategies including head elevation, ventilation control,
sedation, hyperosmolar therapy, and ventricular drainage. If
the raised ICP was resistant to these therapies, then decom-
pressive craniotomy and/or further surgical operation were
adopted. In addition, serum glucose, blood gases, and serum
electrolytes were assessed regularly, with treatment pro-
vided for any abnormal findings. After hypothermia was
discontinued, any patients with fever, defined as body
temperature more than 38 °C, were examined for infectious
or noninfectious causes and treated with ice packs around
the neck and limbs, sponging the body with alcohol, use of
paracetamol, or a combination.
Biomarker determination
Blood samples (3–5 ml) were taken by the study investi-
gators (JL and GG) using red top tubes at the time of
admission (within 4 hours post injury) to the hospital
and then each morning (6:00–8:00 am) for the first
5 days in the NICU. After collection, specimens were
maintained at room temperature for 30–60 minutes and
centrifuged for 10 minutes at 4000 rpm; sera were stored
at −80 °C until analysis.
Serum GFAP concentration was measured using an
enzyme-linked immunosorbent assay (ELISA) via a com-
mercial kit according to the manufacturer’s protocol
(Biovendor, Candler, NC, USA). Briefly, standards, qual-
ity controls (QC-Low and QC-High), and serum samples
were incubated in microplate wells precoated with poly-
clonal anti-human GFAP antibody for 2 hours, followed
by 1 hour incubation with a biotin-labeled monoclonal
anti-human GFAP antibody solution and 1 hour incuba-
tion with a streptavidin–horseradish peroxidase conju-
gate. Between each step, the plate was thoroughly
washed four times with washing buffer. After the last
washing step, the remaining conjugate was allowed to
react with the substrate solution for an additional 15 mi-
nutes. The reaction was stopped by the addition of an
acidic solution, and the absorbance of the resulting
yellow product was measured by reading the ELISA
plate at 450 nm. The absorbance was proportional to the
concentration of GFAP. A standard curve (0.25–25 ng/ml)
was constructed by plotting absorbance values against
concentrations of standards, and concentrations of un-
known samples were determined using this standard
curve. The lower limit for detection in the assay was
0.045 ng/ml. All concentrations below this limit of
detection were reported as zero. The coefficients of vari-
ation for inter- and intra-assay variability were 5.7 % and
5.1 %, respectively. All samples were assayed in duplicate,
and average results were used for analysis.
Data collection and outcome assessment
Demographic and clinical data were collected from patient
medical records including sex, age, and cause of injury,
CT scan, admission GCS score, pupil reactions, and sur-
gery. Initial head CT scans were analyzed and classified
according to the criteria raised by Marshall and associates
[19] to determine brain injury severity (Diffuse injury I: no
visible intracranial pathology; Diffuse injury II: cisterns
present with midline shift of 0–5 mm, no focal lesion
of > 25 ml; Diffuse injury III: cistern compressed or
absent with midline shift of 0–5 mm, no focal lesion
of > 25 ml; Diffuse injury IV: midline shift of > 5 mm,
no focal lesion of > 25 ml; Evacuated mass lesion: any
lesion surgically evacuated; Non-evacuated mass lesion:
lesion of > 25 ml, not surgically evacuated). Since the recent
trial by Clifton et al. [20] reported possible differential ef-
fects of hypothermia among patients with surgical lesion
compared with diffuse injury, the surgical lesion and diffuse
injury groups were further defined based on the above CT
classification in our study to examine the potential correl-
ation between serum GFAP concentration and the patho-
logical types of brain injury and the role of hypothermia.
Neurological outcome assessment was performed by a
blinded investigator (CW) who was unaware of the
patient's clinical history and biomarker data using the
Glasgow Outcome Scale (GOS) at 6 months after injury
with the use of a structured interview by direct patient
contact or via telephone [21]. The GOS is a five-
category scale used for assessing the neurological out-
come after brain injury as follows: 1, death; 2, vegetative
state—unable to interact with the environment; 3, severe
disability—unable to live independently but able to fol-
low commands; 4, moderate disability—capable of living
independently but unable to return to work or school;
and 5, good recovery—able to return to work or school.
For statistical analyses, the outcome was further dichoto-
mized in death (GOS 1) versus survival (GOS 2–5) and
unfavorable (GOS 1–3) versus favorable (GOS 4–5).
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Statistical analysis
Basic descriptive statistics were used to describe the data,
including standard measures of central tendency and
dispersion for continuous data (mean, standard deviation
(SD), median, and range) and frequencies and proportions
for categorical variables. Comparisons were made using
a chi-squared test, Fisher’s exact test, unpaired Student
t test, or Wilcoxon rank-sum test, if appropriate. Signifi-
cance was set at P < 0.05.
To analyze the association of serum GFAP levels
during the first 6-day period and neurological outcomes
at 6-month post injury, we use the longitudinal multiple
linear regression models (also called cross-sectional time
series) that controlled for confounding clinical parame-
ters, which have the ability to provide efficient statistical
power to analyze continuous outcomes (biomarker levels)
that are measured at regular time intervals, which are the
same for all subjects [22]. Serum GFAP levels were logarith-
mically transformed to achieve approximately normal dis-
tribution and treated as the dependent variable. Outcome
group (i.e., death or unfavorable outcome, as defined above)
and time of blood sampling were included in each model
as independent variables. Additional variables, including
age, sex, cause of injury, time from injury to admission,
surgery, baseline GCS score, Marshall CT classification,
and pupil reactions were evaluated as potential con-
founders and included in the models. These models
allowed us to determine whether the injured patients from
dichotomized outcome groups had differing serum GFAP
levels over time.
Receiver operating characteristic (ROC) curve analysis
was performed to determine the discriminatory charac-
teristics of serum GFAP during the course from the day
of admission to day 5. ROC curves were secondarily
developed along with the respective diagnostic parame-
ters of the coordinates of the curve (i.e., sensitivity,
specificity, positive and negative predictive values), the
area under the curve (AUC), and the optimal cutoff
point for the best overall predictive ability (i.e., the sum
of the sensitivity and the specificity for prediction of
outcome was maximal). The AUC value was used to
compare the ability of admission serum GFAP to predict
6-month lethal or unfavorable outcomes compared with
the clinical predictors in the IMPACT core model (i.e.,
age, GCS score, or pupil reactions).
Results
During the period from March 2011 to September 2014,
there were 77 severe TBI patients deemed potentially eli-
gible. Of these, 10 patients were not included in our study
owing to lack of informed consent (n = 3), an age less than
18 years (n = 1), or loss to follow-up (n = 6). A final 67
patients were enrolled in this study. Clinical and demo-
graphic data of the study population are summarized in
Table 1. The subjects ranged between 18 and 70 years of
age (mean age: 37.2 ± 14.3 years), with the majority being
males (n = 51, 76.1 %). Traffic accident was the most com-
mon cause of injury, accounting for 49.3 % of all subjects.
On average, patients were admitted to hospital within
2.6 hours (SD: 1.1, range: 0.5–4) of injury, with a median
admission GCS score of 6 (range: 3–8). Except for three
subjects with missing CT images, 31 of the 64 patients
presented with diffuse injury (Diffuse injury II to IV)
and 33 with focal mass lesion (Evacuated mass lesion,
n = 30; Non-evacuated mass lesion, n = 3) according to
the Marshall classification. For 59 cases, neurosurgical
operation was performed and lasted for a mean (SD)
of 2.6 (1.3) hours (range: 0.5–5). ICP was continuously
monitored by intraventricular (n = 51) or intraparenchy-
mal (n = 16) routes and the value was at least once above
25 mmHg in 34 patients (nine patients with unavailable
data). The neurological outcome was assessed by tele-
phone or regular clinical visit at 6 months later, when 40
of 67 patients were alive, of whom 32 had a favorable out-
come (GOS 4–5). Patients in the lethal or unfavorable
outcome groups were more likely to be older and have a
lower admission GCS score, and abnormal pupils. Other-
wise, there were no significant differences in terms of sex,
cause of trauma, time from injury to admission, Marshall
CT classification, neurosurgical intervention, and duration
of surgery between outcome groups.
Serial blood samples were collected on admission
(D0), days 1 (D1), 2 (D2), 3 (D3), 4 (D4), and 5 (D5) post
injury for the enrolled patients. Nine blood specimens
were not obtained from D0 to D3 (two at D0, four at
D1, three at D2, and two at D3). Four patients died dur-
ing the first 5 days, and thus did not have blood drawn
at either D5 (n = 3) or at both D4 and D5 (n = 1). The
remaining 54 (80.6 %) patients had blood samples col-
lected at all time points. In addition, blood samples were
obtained from 135 healthy blood donors (88 males and
47 females; mean age of 39.2 ± 15.3 years; range: 18–65).
Medians (interquartile range; IQR) for serum GFAP
concentrations in the severe TBI patients from D0 to D5
and healthy subjects were 1.924 (0.891–3.126) ng/ml,
1.079 (0.468–1.880) ng/ml, 0.790 (0.402–1.228) ng/ml,
0.751 (0.438–1.206) ng/ml, 1.006 (0.534–1.529) ng/ml,
0.649 (0.284–0.982) ng/ml, and 0 (0–0) ng/ml, respect-
ively. For healthy individuals, only 12 of 135 serum sam-
ples had detectable GFAP (range: 0.048–0.076 ng/ml;
median: 0.058 ng/ml). The differences in GFAP levels
between TBI patients and controls were highly significant
at all time intervals (P < 0.001 for each comparison).
The time course of serum GFAP levels by the overall
population and each outcome category is presented in
Figs. 1 and 2. The serum GFAP value gradually de-
creased over the first 3 days until the rebound on day 4,
when hypothermia was discontinued with slow rewarming.
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Thirty-eight of the 64 (59.4 %) patients had elevated serum
GFAP level on day 4 compared with day 3 (24 of 33 with
unfavorable outcome versus 14 of 31 with favorable
outcome, respectively, P = 0.016). Serum GFAP levels over
the study period were significantly higher in the patients
who died within 6 months after injury than in those who
were alive or had favorable outcome (Fig. 3). These differ-
ences remained statistically significant after controlling for
covariables, including age, sex, cause of injury, time from
injury to admission, surgery, baseline GCS score, Marshall
CT classification, and pupil reactions. Among these covari-
ables, baseline GCS score and pupil reactions were consist-
ently significant in the models both for death/survival or
unfavorable/favorable outcomes (P < 0.05 for both covari-
ates in the final models).
With regard to the pathological types of TBI based on
the Marshall classification, 31 patients were diagnosed
with diffuse injury (Diffuse injury II–IV) and 30 patients
with surgical lesions (Evacuated mass lesion) on the
initial head CT scan. Table 2 describes the characteris-
tics of both groups. There was a well-matched base-
line between patients with diffuse injury and surgical
lesion, with no differences between groups regarding
the demographic, clinical characteristics, and 6-month
outcome. Serum GFAP concentrations on day 0 were
significantly higher in patients with surgical lesion
compared with patients with diffuse injury (median
(IQR), 2.776 (1.538–3.942) ng/ml vs. 1.151 (0.459–1.847)
ng/ml; P < 0.001). On day 4 after hypothermia treatment,
the GFAP levels decreased to 1.035 (IQR, 0.882–1.663)
ng/ml in the surgical lesion group and to 0.868 (IQR,
0.359–1.265) ng/ml in the diffuse injury group. With
the logarithmically transformed data, there was a
significant difference of reduction in serum GFAP be-
tween groups after controlling for the baseline concen-
tration (P = 0.037).
Table 1 Clinical and demographic characteristics of the 67 studied patients by outcome category at 6 months post injury
Total (n = 67) Death (GOS = 1) Unfavorable outcome (GOS = 1–3)
Yes (n = 27) No (n = 40) P value Yes (n = 35) No (n = 32) P value
Age (yrs, mean ± SD) 37.2 ± 14.3 42.0 ± 16.1 33.9 ± 12.0 0.039 40.0 ± 15.0 34.1 ± 12.9 0.503
Male, n (%) 51 (76.1) 21 (77.8) 30 (75.0) 0.794 28 (80.0) 23 (71.9) 0.436
Cause of injury, n (%)
Traffic accident 33 (49.3) 13 (48.1) 20 (50.0) 0.968 17 (48.6) 16 (50.0) 0.997
Fall 26 (38.8) 11 (40.7) 15 (37.5) 14 (40.0) 12 (37.5)
Violence 6 (8.9) 2 (7.4) 4 (10.0) 3 (8.6) 3 (9.4)
Other 2 (2.9) 1 (3.7) 1 (2.5) 1 (2.9) 1 (3.1)
Time after injury (hrs, mean ± SD) 2.6 ± 1.1 2.6 ± 1.2 2.6 ± 1.1 0.333 2.4 ± 1.2 2.9 ± 1.1 0.791
GCS, median (range) 6 (3–8) 5 (3–8) 7 (3–8) 0.006 5 (3–8) 7 (3–8) 0.001
GCS 3–5, n (%) 25 16 (59.3) 9 (22.5) 0.012 19 (54.3) 6 (18.8) 0.006
GCS 6–8, n (%) 42 11 (40.7) 31 (77.5) 16 (45.7) 26 (81.2)
Pupil reactions, n (%)
Both present 38 10 (37.0) 28 (41.8) 0.015 13 (37.1) 25 (78.1) 0.032
At least one unreactive pupil 29 17 (63.0) 12 (58.2) 22 (62.9) 7 (21.9)
Marshall CT classification, n (%)
Missing 3 (4.5) 1 (3.7) 2 (5) 0.641 1 (2.9) 2 (6.3) 0.406
Diffuse injury I 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Diffuse injury II 7 (10.4) 3 (11.1) 4 (10) 4 (11.4) 3 (9.4)
Diffuse injury III 11 (16.4) 6 (22.2) 5 (12.5) 6 (17.1) 5 (15.6)
Diffuse injury IV 13 (19.4) 6 (22.2) 7 (17.5) 10 (28.6) 3 (9.4)
Evacuated mass lesion 30 (44.8) 11 (40.7) 19 (47.5) 13 (37.1) 17 (53.1)
Non-evacuated mass lesion 3 (4.5) 0 (0) 3 (7.5) 1 (2.9) 2 (6.3)
Neurosurgery, n (%)
Yes 59 (88.1) 25 (92.6) 34 (85.0) 0.347 33 (94.3) 26 (81.3) 0.100
No 8 (11.9) 2 (7.4) 6 (15.0) 2 (5.7) 6 (18.7)
Duration of neurosurgery, (hrs, mean ± SD)a 2.6 ± 1.3 3.1 ± 1.2 2.3 ± 1.3 0.704 3.2 ± 1.2 1.9 ± 1.0 0.216
GOS Glasgow Outcome Scale, yrs years, SD standard deviation, hrs hours, GCS Glasgow Coma Scale, CT computed tomography
aDocumented in 59 of 67 patients
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Figure 4 shows the ROC analyses of serum levels of
GFAP on days 0, 1, 2, 3, 4, and 5 post injury. AUC data on
each day are also plotted. The AUC values in serum GFAP
were significantly greater than 0.5 at each time point (P <
0.05), which ranged from 0.689 to 0.774 for death and
from 0.693 to 0.851 for unfavorable outcome (Fig. 4a and
c). Consistent with the change in serum levels of GFAP in
the first 6 days, AUC values also showed a similar
decrease from D0 to D3 and then a further increase on
D4 (Fig. 4b and d). Interestingly, serum GFAP on D4 (the
day after hypothermia) had much higher AUC values than
for D0, which may suggest the potential clinical utility of
delayed determination of biomarkers after a certain inter-
vention. The predictive ability of serum GFAP at the time
of admission was good, with AUCs of 0.761 (95 % CI,
0.606–0.917) for death and 0.823 (95 % CI, 0.700–0.947)
for unfavorable outcome. These values were higher com-
pared with the clinical variables including age, GCS score,
and pupil reactions in both predictions of death and
unfavorable outcome (Table 3).
The optimal cutoff point and associated diagnostic char-
acteristics for serum GFAP levels on admission were
calculated from the coordinates of the ROC curve for the
best overall predictive performance of outcomes. Using
the cutoff value of 1.690 ng/ml, serum GFAP on admis-
sion had a sensitivity of 84.6 % and specificity of 69.2 %
for predicting death, with a positive predictive value (PPV)
of 64.7 % and a negative predictive value (NPV) of 87.1 %.
For prediction of unfavorable outcome at 6 months
post injury, admission GFAP (the optimal cutoff value,
1.559 ng/ml) had a sensitivity of 85.3 %, specificity of
77.4 %, PPV of 80.6 % and NPV of 82.8 % (Table 3).
Discussion
Improving the prognosis for patients with acute TBI is crit-
ical [23] as TBI remains a devastating disease associated
Fig. 2 Serum GFAP levels by each outcome group over the first 6 days post injury, shown as box plots. D0, D1, D2, D3, D4, and D5 represent the
admission day and days 1–5 post injury, respectively. Box and whisker plots show median, interquartile range (IQR), and values within ± 1.5 of IQR.
Outliers are plotted as open circles. The number under each box is the number of samples available for analysis. Hypothermia was induced in patients
when admitted into the NICU, and was maintained for the first 3 days then terminated with slow rewarming. GFAP glial fibrillary acidic protein, NICU
neurosurgical intensive care unit
Fig. 1 Serum GFAP levels by the overall population during the first
6 days post injury. D0, D1, D2, D3, D4, and D5 represent the admission
day and days 1–5 post injury, respectively. Box and whisker plots show
median, interquartile range (IQR), and values within ± 1.5 of IQR.
Outliers are plotted as open circles. The number under each box is the
number of samples available for analysis. Hypothermia was induced in
patients when admitted into the NICU, and was maintained for the
first 3 days then terminated with slow rewarming. GFAP glial fibrillary
acidic protein, NICU neurosurgical intensive care unit
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Fig. 3 Median serum GFAP levels by categorized outcome groups. a Death versus survival. b Unfavorable versus favorable outcome. Error bars show
interquartile ranges. GFAP glial fibrillary acidic protein
Table 2 Patient characteristics between diffuse injury and surgical lesion group
Diffuse injury Surgical lesion P
value(n = 31) (n = 30)
Age (yrs, mean ± SD) 35.1 ± 14.3 40.6 ± 14.9 0.917
Male, n (%) 24 (77.4) 23 (76.7) 0.944
GCS, median (range) 6 (3–8) 6 (3–8) 0.071
GCS 3–5, n (%) 10 (32.3) 14 (46.7) 0.300
GCS 6–8, n (%) 21 (67.7) 16 (53.3)
Pupil reactions, n (%)
Both present 20 (64.5) 13 (43.3) 0.126
At least one unreactive pupil 11 (35.5) 17 (56.7)
6-month outcome, n (%)
Death/alive 15 (48.4)/16 (51.6) 11 (36.7)/19 (63.3) 0.440
Unfavorable/favorable 20 (64.5)/11 (35.5) 13 (43.3)/17 (56.7) 0.202
Yrs years, SD standard deviation, GCS Glasgow Coma Scale
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Fig. 4 Receiver operating curves (ROC) for serum GFAP from the admission day to day 5 post injury and prediction of death (a) and unfavorable outcome
(c). Each day has a representative curve. The area under the curve (AUC) over time was also plotted (b and d). GFAP glial fibrillary acidic protein
Table 3 Predictive values of admission serum GFAP and clinical variables for death and unfavorable outcome at 6 months of injury
Death (GOS = 1) Unfavorable outcome (GOS = 1–3)
Variable Cutoff Sensitivity Specificity PPV NPV AUC (95 % CI) Cutoff Sensitivity Specificity PPV NPV AUC (95 % CI)
GFAP (ng/ml) 1.690 84.6 69.2 64.7 87.1 0.761 (0.606, 0.917) 1.559 85.3 77.4 80.6 82.8 0.823 (0.700, 0.947)
Age (years) 44.5 44.4 82.5 63.2 68.8 0.592 (0.503, 0.681) 39.5 45.7 65.6 59.3 52.5 0.617 (0.482, 0.751)
GCS score 4.5 90.0 48.1 72.0 76.5 0.742 (0.616, 0.868) 5.5 81.3 54.3 61.9 76.0 0.751 (0.620, 0.862)
Pupil reactions Absent 70.0 63.0 73.7 58.6 0.665 (0.530, 0.800) Absent 78.1 62.9 65.8 75.9 0.705 (0.578, 0.832)
The (optimal) cutoff values were determined using receiver operating characteristic curve under the condition of equal costs of misclassification of cases and non-cases;
i.e., the sum of the sensitivity and the specificity to predict the chosen outcome category was maximal
GFAP glial fibrillary acidic protein, GOS Glasgow Outcome Scale, PPV positive predictive value, NPV negative predictive value, AUC area under the curve,
CI confidence interval, GCS Glasgow Coma Scale
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with considerable mortality and morbidity and a huge
burden to society, and there are no interventions that
show substantial efficacy despite of hundreds of trials
[24, 25]. Although hypothermia shows the most clinical
promise for improving patient outcomes, the optimal clin-
ical protocols remain unclear [26]. The use of biomarkers
may help to detect, track cellular damage and cerebral
protection in the injured brain, and to balance the risks
and benefits of therapeutic interventions.
Biomarkers can also be used to provide outcome predic-
tion and risk triage. Current assessment tools include
clinical characteristics (e.g., age, sex, reaction of the pupils,
GCS score, and secondary insults), radiological data, and
electroencephalography, which provide some predictive
information. However, there are inherent limitations in
these procedures. Clinical examinations are usually sub-
jective and are often confounded by medications such as
sedation, intubation/tracheostomy, and muscle relaxants,
making them less reliable in the setting of the state-of-
the-art critical management including hypothermia and
early sedation. Head CT scanning, magnetic resonance
imaging, or eletroencephalography often require special-
ized equipment or technical/interpretive expertise that
may not be available at resource-limited medical centers.
Further, they do not offer adequate information on the
biochemical changes in the brain [27]. Thus, identification
of valid neurobiochemical markers of brain injury that
serve as surrogates of the presence, evolution, and out-
comes of brain injury is key to the research and treatment
of TBI patients.
GFAP, a brain-specific protein that functions as the major
integral component of the cytoskeleton of astrocytes, has
been recently reported as a blood biomarker. After brain
damage, GFAP is released from degenerating brain cells
into the surrounding interstitial fluid and appear in the
peripheral blood, likely via disruptions in the blood–brain
barrier [28]. Elevated serum GFAP can provide diagnostic
and prognostic information in a range of neurological
diseases including neurodegenerative disorders [29], stroke
[30], and severe TBI [31]. In line with previous reports, our
study in a cohort of 67 patients with severe TBI demon-
strated that elevated serum GFAP on admission and during
the subsequent 5 days had a strong correlation with death
and unfavorable outcome at 6 months post injury, which
was independent of baseline and clinical characteristics of
brain injury. Additionally, our study also indicates that the
predictive accuracy of admission GFAP was greater than
those of clinical variables including age, GCS score, and
pupil reactions, which may provide further evidence about
the utility of GFAP in the care of TBI patients.
Induction of mild hypothermia immediately after brain
injury can reduce cerebral metabolism and oxygen con-
sumption, diminish cytotoxic edema, stabilize the blood–
brain barrier, and improve histological and functional
outcomes and survival in numerous animal and clinical
studies [32]. Mild hypothermia is now an accepted treat-
ment for anoxic brain injury following cardiac arrest
and neonatal hypoxic-ischemic encephalopathy [33, 34].
Although recent multicenter trials have reported negative
results for treatment of severe TBI with hypothermia,
numerous single-center studies and several later meta-
analyses support its neuroprotective actions, especially
when maintained for longer than 48 hours [20, 35, 36].
Apart from the insensitive methodology or potential
biases such as center effects in these multicenter trials,
the most likely explanation for these conflicting results
is the different protocols of hypothermia therapy used
clinically or the heterogeneous types of TBI patients
enrolled [37]. For example, in a recent large clinical trial
by Clifton and colleagues [20], a post hoc subgroup ana-
lysis (28 patients were allowed for analysis, 15 of whom
treated by hypothermia) suggested a specific beneficial
effect of hypothermia in patients with surgically evacuated
hematoma. Yokobori et al. also reported that hypothermia
could reduce histological and biochemical injury to neu-
rons and glia in a rat model of acute hematoma of severe
TBI [38]. In the present study, although the long-term
neurological outcomes did not show any differences
between patients with surgical lesion and diffuse injury,
the change in serum GFAP before and after hypothermia
was significantly greater among patients with surgical
lesion, suggesting a more profound neuroprotective effect
of hypothermia among this group of patients. Thus,
supported by the above evidence and our present data, a
further study, targeted specifically on the type of surgical
lesion, is warranted to investigate the different effect of
hypothermia in the setting of TBI.
We found a persistent reduction of serum GFAP level
during the first few days after TBI in hypothermia-treated
patients in both the favorable and unfavorable outcome
groups. However, as we did not have a normothermia-
treated control group, this reduction may also be attrib-
uted to altered permeability of the blood–brain barrier
due to hypothermia [39], or the natural temporal alter-
ations of serum GFAP in TBI patients, rather than solely
to a neuroprotective effect of hypothermia. Future studies
are required to examine the effect of hypothermia on
serum concentrations of biochemical markers and the
correlation of the altered levels and long-term neuro-
logical outcomes. Our ongoing LTH-1 hypothermia trial
and collection of biofluid samples of patients has the
potential to address this issue in the future [40].
The marked increase of serum GFAP levels at the con-
clusion of the 3-day maintenance period of hypothermia
was observed in 38 of 64 patients, 24 of whom had
unfavorable outcome at 6 months post injury, suggesting
that continued secondary injury in these cases that was
suppressed by cooling therapy or the possible evidence
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of rewarming injury. Thus, these 38 patients may benefit
from alterations in hypothermia protocols including
longer cooling or more advanced rewarming procedures.
The optimal duration and rewarming rate of hypothermia
for severe TBI are extremely important issues to be
addressed, as numerous studies report that effective
hypothermia treatment in TBI patients requires early initi-
ation, with suitable length of cooling and steady rewarm-
ing [41]. As there are no reliable surrogate markers for
monitoring the pathophysiology of the injured brain,
gauging response to treatment, and comparing the effects
of various hypothermia protocols, it is possible that circu-
lating injury markers like GFAP will help to bridge this gap.
The cutoff value we found for admission serum GFAP
to predict unfavorable outcome at 6 months was
1.559 ng/ml, similar to the 1.5 ng/ml reported by Vos
and colleagues [9, 31]. However, a wide range of cutoff
points from 1.5 to 6.98 ng/ml have been reported, lead-
ing to different sensitivities and specificities for this pro-
tein, which limits the utility of GFAP as a reliable
predictor in clinical practice [14, 16, 42]. To address this
problem, further validation studies in a larger sample of
participants is required, using standardized assays with
well-established, consistent, and clinically interpretable
thresholds for GFAP alterations.
There are several limitations of our study. First, we
enrolled a relatively limited sample of patients with se-
vere TBI, a disease with extremely intrinsic heterogen-
eity. With this small sample size and the observational
study design, we failed to detect significant differences
in long-term outcomes between patients with surgical
lesions and diffuse injury, and observed inconsistency
between biomarker changes and long-term outcomes.
Second, it is unclear whether the ELISA kit used to
measure the serum GFAP cross-reacts with GFAP break-
down products (GFAP-BDPs). A study in 108 samples
assessing the utility of serum GFAP-BDPs found a
detectable increase in the blood within an hour of head
injury, which was associated with injury severity and CT
lesions [43]. This may alter the final interpretation for
the predictive ability of the intact GFAP in our study.
Third, serum biomarker alterations may not completely
reflect the biochemical changes in the injured brain as
they can be influenced by various factors including the
integrity of the blood–brain barrier or other factors that
regulate the release of proteins into the peripheral circu-
lation in the settings of brain injury and hypothermia.
However, a high correlation between GFAP concentra-
tion in serum and cerebrospinal fluid (CSF) was reported
[44]. Further, serial sampling of CSF is often contraindi-
cated in patients with severe TBI, especially with obvious
intracranial hypertension. Therefore, serum analysis may
have more clinical advantages than CSF measurement
and should be considered in future clinical studies.
Fourth, several technical variables should be considered,
such as time to process the blood sample, effect of
temperature change, and methodology of measurement,
which can affect the stability and reliability of results.
Fifth, a control group of severe TBI patients without
hypothermia treatment was not included in our study.
Thus, we could not determine the possible effect of
hypothermia on serum GFAP levels for TBI patients.
Finally, some patient serum specimens were unable to
be obtained on some days. However, the effect of
missing samples on the whole analysis may be min-
imal owing to the sensitive statistical methodology we
used.
Conclusions
Our study suggests that serum GFAP might be a useful
biochemical marker for severe TBI patients. Elevated
serum GFAP on admission and over a range of days post
injury was a strong predictor for death and unfavorable
outcome at 6 months. Because of increasing clinical
evidence that GFAP is highly brain-specific and shows
diagnostic, prognostic, and even theranostic utility for
clinicians, further studies should be encouraged to fully
elucidate the basic mechanisms and validate the poten-
tial role of GFAP as a biomarker for TBI.
Key messages
 Serum GFAP levels on admission and the first
5 days were elevated among patients with severe
TBI compared with controls.
 Elevated serum GFAP levels over the first 6 days
had predictive power for neurological outcome at
6 months post injury.
 Admission GFAP levels had greater predictive ability
than clinical characteristics including age, GCS
score, and pupil reactions.
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